ArticleCureus2025
Evaluation of iStent Inject® Trabecular Microbypass Stent Implantation With Phacoemulsification in Cases of Mild to Moderate Primary Open-Angle Glaucoma (POAG).
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe iStent inject® (second generation) is an example of a minimally invasive glaucoma surgery (MIGS) device being increasingly used in the management of glaucoma. It is a recent advancement in the field of glaucoma treatment and can be performed simultaneously with cataract surgery.
objectivesThe primary objective is to evaluate the change in intraocular pressure (IOP), with secondary objectives to assess the medication burden and safety profile of the implantation of the two second-generation iStent inject trabecular microbypass stents with concomitant phacoemulsification.
methodsA service evaluation of the procedure was conducted over multiple hospital sites across the East Kent Hospitals University NHS Foundation Trust. A data set of 102 eyes was generated, which underwent combined phacoemulsification and iStent inject implantation under three iStent surgeons. This data set included information on preoperative and postoperative IOP, complications, and the number of glaucoma medications established.
resultsThere was a reduction of 43.5% in mean IOP in the 102 eyes from a preoperative IOP mean of 22.0 ± 8.54 mmHg (mean ± standard deviation) to a postoperative IOP of 12.4 ± 4.21 mmHg (p < 0.001). There was a reduction in the mean number of medications in the overall cohort by 11.7% from 2.74 ± 1.15 preoperatively to 2.42 ± 1.01 postoperatively (p < 0.001). Ninety (88.2%) eyes had a reduction of ≥20% in IOP. No intraoperative complications were recorded, and two (2%) eyes developed cystoid macular oedema (CMO) postoperatively. There were no other adverse effects or complications reported.
conclusionsSignificant reductions in IOP and medication burden were identified in this cohort of 102 eyes. It has been observed to be a safe surgery with a high safety profile. The utilization of this concomitant surgery could help reduce the number of follow-ups required for patients with glaucoma compared to exclusively medical control or advanced glaucoma surgery and lead to significantly less theater time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.